Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Boehringer Ingelheim
Baxter
Cantor Fitzgerald
Medtronic

Generated: September 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,294,215

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,294,215 protect, and when does it expire?

Patent 10,294,215 protects IDHIFA and is included in one NDA.

This patent has forty-six patent family members in thirty-three countries.

Summary for Patent: 10,294,215
Title:Therapeutically active compounds and their methods of use
Abstract: Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Inventor(s): Cianchetta; Giovanni (Waltham, MA), DeLaBarre; Byron (Arlington, MA), Popovici-Muller; Janeta (Waltham, MA), Salituro; Francesco G. (Marlborough, MA), Saunders; Jeffrey O. (Lincoln, MA), Travins; Jeremy (Southborough, MA), Yan; Shunqi (Irvine, CA), Guo; Tao (Dayton, NJ), Zhang; Li (Shanghai, CN)
Assignee: Agios Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:15/638,279
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 10,294,215

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-001 Aug 1, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION ➤ Sign Up
Celgene Corp IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Baxter
Johnson and Johnson
Daiichi Sankyo
Farmers Insurance
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.